J Clin Med Res

Journal of Clinical Medicine Research, ISSN 1918-3003 print, 1918-3011 online, Open Access

Article copyright, the authors; Journal compilation copyright, J Clin Med Res and Elmer Press Inc

Journal website http://www.jocmr.org

Original Article

Volume 6, Number 5, October 2014, pages 327-335

Effect of Sitagliptin on Lipid Profile in Patients With Type 2 Diabetes Mellitus

Figure 1. The correlation between change of HbA_1c and lipid at week 12. TC: total cholesterol; LDL-C: LDL-cholesterol; non-HDL-C: non-HDL-cholesterol.

**Table 1.** Clinical and Laboratory Characteristics at Baseline and After Treatment With Sitagliptin
	Baseline	12 weeks	% Change from baseline 12 weeks
Age (years)	61.8 ± 33.9
Sex, men/women	247/138
Height (cm)	162.0 ± 9.2
Weight (kg)	64.5 ± 14.5	64.3 ± 14.0	-0.5 ± 5.1
BMI (kg/m²)	24.4 ± 4.3
Blood levels
TC (mg/dL)	187.5 ± 46.3	178.1 ± 40.1*	-3.0 ± 15.6*
LDL-C (mg/dL)	106.7 ± 34.6	98.8 ± 28.7*	-2.5 ± 27.7
HDL-C (mg/dL)	51.0 ± 13.7	51.1 ± 13.8	-0.9 ± 16.4
TG (mg/dL)	163.9 ± 119.6	158.3 ± 128.0	1.4 ± 44.4
Non-HDL-C (mg/dL)	136.1 ± 43.1	127.1 ± 36.9*	-2.9 ± 19.7*
Glucose (mg/dL)	175.3 ± 64.0	148.7 ± 50.1*	-8.7 ± 33.5*
HbA_1c (NGSP) (%)	8.4 ± 1.6	7.3 ± 1.0*	-10.5 ± 12.3*

Table 1. Clinical and Laboratory Characteristics at Baseline and After Treatment With Sitagliptin

Baseline

12 weeks

% Change from baseline
12 weeks

Age (years)

61.8 ± 33.9

Sex, men/women

247/138

Height (cm)

162.0 ± 9.2

Weight (kg)

64.5 ± 14.5

64.3 ± 14.0

-0.5 ± 5.1

BMI (kg/m²)

24.4 ± 4.3

Blood levels

TC (mg/dL)

187.5 ± 46.3

178.1 ± 40.1*

-3.0 ± 15.6*

LDL-C (mg/dL)

106.7 ± 34.6

98.8 ± 28.7*

-2.5 ± 27.7

HDL-C (mg/dL)

51.0 ± 13.7

51.1 ± 13.8

-0.9 ± 16.4

TG (mg/dL)

163.9 ± 119.6

158.3 ± 128.0

1.4 ± 44.4

Non-HDL-C (mg/dL)

136.1 ± 43.1

127.1 ± 36.9*

-2.9 ± 19.7*

Glucose (mg/dL)

175.3 ± 64.0

148.7 ± 50.1*

-8.7 ± 33.5*

HbA_1c (NGSP) (%)

8.4 ± 1.6

7.3 ± 1.0*

-10.5 ± 12.3*

**Table 2.** Percentage Change From Baseline at Week 12 With Different Backgrounds
	TC	TG	HDL-C	LDL-C	Non-HDL-C
The mean ± SD, *P < 0.05.
Age
< 65 (135)	-3.2 ± 15.5	-2.1 ± 33.0	-1.5 ± 13.9	1.1 ± 41.2	-2.9 ± 20.6
≥ 65 (113)	-3.0 ± 15.8	-3.2 ± 20.1	-0.3 ± 19.1	1.5 ± 48.2	-3.2 ± 18.6
Sex
Male (159)	-2.8 ± 15.3	-1.9 ± 31.1	-1.9 ± 14.1	4.4 ± 49.5	-2.6 ± 19.7
Female (89)	-3.4 ± 16.3	-3.6 ± 21.0	0.8 ± 19.9	-3.9 ± 32.9	-3.5 ± 19.9
BMI
< 25 (119)	-4.2 ± 14.7	-2.0 ± 33.5	-1.4 ± 17.2	-0.6 ± 42.8	-4.4 ± 17.7
≥ 25 (99)	-1.9 ± 16.4	-3.4 ± 20.4	-2.0 ± 15.2	5.1 ± 46.7	-1.1 ± 21.5
Non-Mets (179)	-2.1 ± 14.8	4.7 ± 45.9	-0.7 ± 17.4	-0.6 ± 30.0	-1.6 ± 18.1
Mets (54)	-3.8 ± 17.7	-5.2 ± 42.0	-1.7 ± 14.3	-6.4 ± 18.9	-4.3 ± 24.1
Baseline TC
< 220 (207)	-0.9 ± 15.3	0.6 ± 28.6	-0.7 ± 16.8	2.5 ± 43.0	-0.2 ± 19.4
≥ 220 (41)	-13.6 ± 13.0*	-17.3 ± 17.0*	-1.8 ± 14.7	-4.2 ± 51.6	-16.4 ± 15.6*
Baseline LDL-C
< 120 (186)	-0.4 ± 15.5	1.7 ± 29.3	-1.1 ± 17.0	3.5 ± 43.5	0.6 ± 19.5
≥ 120 (60)	-11.0 ± 13.4*	-15.2 ± 17.4*	-0.5 ± 14.9	-6.5 ± 46.8	-13.8 ± 16.1*
Baseline HDL-C
< 40 (42)	1.1 ± 19.1	7.5 ± 50.8	9.7 ± 23.1*	-7.2 ± 35.6	-0.9 ± 21.6
≥ 40 (203)	-3.9 ± 14.9	-4.4 ± 19.5*	-3.2 ± 13.8	2.4 ± 45.7	-3.4 ± 19.3
Baseline TG
< 150 (138)	-0.8 ± 14.1	-0.4 ± 20.0	-1.4 ± 16.2	9.1 ± 49.5	0.3 ± 17.4
≥ 150 (110)	-5.6 ± 17.0*	-4.8 ± 35.2	-0.4 ± 16.9	-8.3 ± 39.7*	-7.0 ± 21.7*
Antihyperlipidemic drug
No (113)	-2.5 ± 15.0	-2.2 ± 33.0	0.4 ± 16.6	2.5 ± 47.1	-3.0 ± 19.4
Yes (115)	-3.6 ± 16.4	-3.0 ± 20.3	-2.5 ± 16.2	0.1 ± 41.2	-2.8 ± 20.1
Statin
Mild (21)	3.8 ± 15.9	6.0 ± 43.4	8.5 ± 16.8	1.9 ± 16.9	2.7 ± 18.3
Strong (78)	-5.4 ± 17.1*	1.3 ± 4.28	-5.0 ± 16.2*	-4.8 ± 22.4	-4.1 ± 21.7

Table 2. Percentage Change From Baseline at Week 12 With Different Backgrounds

HDL-C

LDL-C

Non-HDL-C

The mean ± SD, *P < 0.05.

Age

< 65 (135)

-3.2 ± 15.5

-2.1 ± 33.0

-1.5 ± 13.9

1.1 ± 41.2

-2.9 ± 20.6

≥ 65 (113)

-3.0 ± 15.8

-3.2 ± 20.1

-0.3 ± 19.1

1.5 ± 48.2

-3.2 ± 18.6

Sex

Male (159)

-2.8 ± 15.3

-1.9 ± 31.1

-1.9 ± 14.1

4.4 ± 49.5

-2.6 ± 19.7

Female (89)

-3.4 ± 16.3

-3.6 ± 21.0

0.8 ± 19.9

-3.9 ± 32.9

-3.5 ± 19.9

BMI

< 25 (119)

-4.2 ± 14.7

-2.0 ± 33.5

-1.4 ± 17.2

-0.6 ± 42.8

-4.4 ± 17.7

≥ 25 (99)

-1.9 ± 16.4

-3.4 ± 20.4

-2.0 ± 15.2

5.1 ± 46.7

-1.1 ± 21.5

Non-Mets (179)

-2.1 ± 14.8

4.7 ± 45.9

-0.7 ± 17.4

-0.6 ± 30.0

-1.6 ± 18.1

Mets (54)

-3.8 ± 17.7

-5.2 ± 42.0

-1.7 ± 14.3

-6.4 ± 18.9

-4.3 ± 24.1

Baseline TC

< 220 (207)

-0.9 ± 15.3

0.6 ± 28.6

-0.7 ± 16.8

2.5 ± 43.0

-0.2 ± 19.4

≥ 220 (41)

-13.6 ± 13.0*

-17.3 ± 17.0*

-1.8 ± 14.7

-4.2 ± 51.6

-16.4 ± 15.6*

Baseline LDL-C

< 120 (186)

-0.4 ± 15.5

1.7 ± 29.3

-1.1 ± 17.0

3.5 ± 43.5

0.6 ± 19.5

≥ 120 (60)

-11.0 ± 13.4*

-15.2 ± 17.4*

-0.5 ± 14.9

-6.5 ± 46.8

-13.8 ± 16.1*

Baseline HDL-C

< 40 (42)

1.1 ± 19.1

7.5 ± 50.8

9.7 ± 23.1*

-7.2 ± 35.6

-0.9 ± 21.6

≥ 40 (203)

-3.9 ± 14.9

-4.4 ± 19.5*

-3.2 ± 13.8

2.4 ± 45.7

-3.4 ± 19.3

Baseline TG

< 150 (138)

-0.8 ± 14.1

-0.4 ± 20.0

-1.4 ± 16.2

9.1 ± 49.5

0.3 ± 17.4

≥ 150 (110)

-5.6 ± 17.0*

-4.8 ± 35.2

-0.4 ± 16.9

-8.3 ± 39.7*

-7.0 ± 21.7*

Antihyperlipidemic drug

No (113)

-2.5 ± 15.0

-2.2 ± 33.0

0.4 ± 16.6

2.5 ± 47.1

-3.0 ± 19.4

Yes (115)

-3.6 ± 16.4

-3.0 ± 20.3

-2.5 ± 16.2

0.1 ± 41.2

-2.8 ± 20.1

Statin

Mild (21)

3.8 ± 15.9

6.0 ± 43.4

8.5 ± 16.8

1.9 ± 16.9

2.7 ± 18.3

Strong (78)

-5.4 ± 17.1*

1.3 ± 4.28

-5.0 ± 16.2*

-4.8 ± 22.4

-4.1 ± 21.7

**Table 3.** Linear Regression of Predictors of Change at Week 12
	Univariate	Multivariate
<TC>
Age < 65 vs. ≥ 65	-1.2 (-7.5, 5.2)	0.719
Sex male vs. female	-3.7 (-9.9, 2.5)	0.243
BMI < 25 vs. ≥ 25	-1.0 (-7.2, 5.3)	0.765
Mets vs. non-Mets	-4.4 (-11.3, 2.5)	0.214
TC ≥ 220 vs. < 220	-15.3 (-26.3, -4.3)	0.007	-8.6 (-22.8, 5.6)	0.238
LDL-C ≥120 vs. <120	-11.8 (-21.1, -2.6)	0.012	-6.1 (-17.9, 5.7)	0.309
HDL-C ≥ 40 vs. < 40	-3.2 (-12.1, 5.7)	0.481
TG ≥ 150 vs. < 150	-9.4 (-15.4, -3.4)	0.002	-7.0 (-12.8, 1.1)	0.02
Statin strong vs. mild	-7.8 (-14.3, -1.4)	0.017	-8.6 (-14.6, -2.6)	0.005
<LDL-C>
Age < 65 vs. ≥ 65	-2.1 (-9.5, 5.3)	0.582
Sex male vs. female	-5.8 (-13.1, 1.5)	0.120
BMI < 25 vs. ≥ 25	0.1 (-7.3, 7.5)	0.976
Mets vs. non-Mets	-7.1 (-15.2, 1.0)	0.085
TC ≥ 220 vs. < 220	-14.5 (-27.6, -1.4)	0.031	-2.0 (-1.87, 14.7)	0.817
LDL-C ≥ 120 vs. < 120	-14.5 (-25.4, -3.7)	0.009	-11.9 (-25.8, 2.0)	0.095
HDL-C ≥ 40 vs. < 40	-0.5 (-11.0, 10.1)	0.932
TG ≥ 150 vs. < 150	-12.0 (-19.0, -5.0)	0.001	-9.7 (-16.6, -2.8)	0.006
Statin strong vs. mild	-8.7 (-16.3, 1.1)	0.025	-9.5 (-16.5, -2.4)	0.008
<Non-HDL-C>
Age < 65 vs. ≥ 65	-0.4 (-8.0, 7.2)	0.916
Sex male vs. female	-4.7 (-12.2, 2.8)	0.222
BMI < 25 vs. ≥ 25	-2.4 (-9.9, 5.2)	0.540
Mets vs. non-Mets	-5.6 (-13.9, 2.8)	0.190
TC ≥ 220 vs. < 220	-18.8 (-32.0, -5.5)	0.005	-5.8 (-23.1, 11.6)	0.515
LDL-C ≥ 120 vs. < 120	-16.7 (-27.7, -5.7)	0.003	-9.6 (-24.0, 4.8)	0.191
HDL-C ≥ 40 vs. < 40	0.0 (-10.8, 10.8)	0.998
TG ≥ 150 vs. < 150	-13.3 (-20.4, -6.2)	0	-11.1 (-18.2, -3.9)	0.002
Statin strong vs. mild	-6.6 (-14.4,1.3)	0.103

Table 3. Linear Regression of Predictors of Change at Week 12

Univariate

Multivariate

Coefficient (95% CI)

P value

Coefficient (95% CI)

P value

<TC>

Age < 65 vs. ≥ 65

-1.2 (-7.5, 5.2)

0.719

Sex male vs. female

-3.7 (-9.9, 2.5)

0.243

BMI < 25 vs. ≥ 25

-1.0 (-7.2, 5.3)

0.765

Mets vs. non-Mets

-4.4 (-11.3, 2.5)

0.214

TC ≥ 220 vs. < 220

-15.3 (-26.3, -4.3)

0.007

-8.6 (-22.8, 5.6)

0.238

LDL-C ≥120 vs. <120

-11.8 (-21.1, -2.6)

0.012

-6.1 (-17.9, 5.7)

0.309

HDL-C ≥ 40 vs. < 40

-3.2 (-12.1, 5.7)

0.481

TG ≥ 150 vs. < 150

-9.4 (-15.4, -3.4)

0.002

-7.0 (-12.8, 1.1)

0.02

Statin strong vs. mild

-7.8 (-14.3, -1.4)

0.017

-8.6 (-14.6, -2.6)

0.005

<LDL-C>

Age < 65 vs. ≥ 65

-2.1 (-9.5, 5.3)

0.582

Sex male vs. female

-5.8 (-13.1, 1.5)

0.120

BMI < 25 vs. ≥ 25

0.1 (-7.3, 7.5)

0.976

Mets vs. non-Mets

-7.1 (-15.2, 1.0)

0.085

TC ≥ 220 vs. < 220

-14.5 (-27.6, -1.4)

0.031

-2.0 (-1.87, 14.7)

0.817

LDL-C ≥ 120 vs. < 120

-14.5 (-25.4, -3.7)

0.009

-11.9 (-25.8, 2.0)

0.095

HDL-C ≥ 40 vs. < 40

-0.5 (-11.0, 10.1)

0.932

TG ≥ 150 vs. < 150

-12.0 (-19.0, -5.0)

0.001

-9.7 (-16.6, -2.8)

0.006

Statin strong vs. mild

-8.7 (-16.3, 1.1)

0.025

-9.5 (-16.5, -2.4)

0.008

<Non-HDL-C>

Age < 65 vs. ≥ 65

-0.4 (-8.0, 7.2)

0.916

Sex male vs. female

-4.7 (-12.2, 2.8)

0.222

BMI < 25 vs. ≥ 25

-2.4 (-9.9, 5.2)

0.540

Mets vs. non-Mets

-5.6 (-13.9, 2.8)

0.190

TC ≥ 220 vs. < 220

-18.8 (-32.0, -5.5)

0.005

-5.8 (-23.1, 11.6)

0.515

LDL-C ≥ 120 vs. < 120

-16.7 (-27.7, -5.7)

0.003

-9.6 (-24.0, 4.8)

0.191

HDL-C ≥ 40 vs. < 40

0.0 (-10.8, 10.8)

0.998

TG ≥ 150 vs. < 150

-13.3 (-20.4, -6.2)

-11.1 (-18.2, -3.9)

0.002

Statin strong vs. mild

-6.6 (-14.4,1.3)

0.103